Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of DA-2811 in Type 2 Diabetes with Inadequate Glycemic Control
NCT07239440Phase 2Not yet recruiting
- Sponsor
- Dong-A ST
- Start
- Nov 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dapagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Dong-A ST. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07239440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07239440.